Skip to content
Review Open access

CRISPR‐Based Point‐of‐Care Diagnostics: Cas12, Cas13, Cas14, Microfluidics, and Comparison with PCR

Aug 2026 · ChemistrySelect · Vol 11 · 0 citations · 13 references

TL;DR

This review summarizes recent advances in CRISPR‐based diagnostics, focusing on Cas12, Cas13, and Cas14, along with key platforms including SHERLOCK, DETECTR, and FELUDA, and discusses their integration with POC technologies such as microfluidic devices, lateral‐flow assays, and smartphone‐based detection systems.

Abstract

Conventional molecular diagnostics, particularly polymerase chain reaction (PCR), remain the gold standard for pathogen detection but are often unsuitable for rapid point‐of‐care (POC) testing because they require specialized equipment and laboratory infrastructure. CRISPR‐Cas systems have emerged as powerful alternatives, offering rapid, accurate, and programmable molecular diagnostics with strong potential for decentralized healthcare. This review summarizes recent advances in CRISPR‐based diagnostics, focusing on Cas12, Cas13, and Cas14, along with key platforms including SHERLOCK, DETECTR, and FELUDA. We discuss their integration with POC technologies such as microfluidic devices, lateral‐flow assays, and smartphone‐based detection systems. Their performance is compared with PCR in terms of sensitivity, specificity, turnaround time, and operational requirements. CRISPR‐based assays demonstrate PCR‐comparable accuracy while enabling isothermal amplification and results within 30–60 minutes. These technologies have supported rapid lateral‐flow testing and received emergency authorization from regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the Indian Council of Medical Research (ICMR), for SARS‐CoV‐2 detection. Despite these advances, challenges such as multiplex detection, reagent stability under ambient conditions, and large‐scale clinical validation remain. Continued improvements in these areas will be essential for translating CRISPR diagnostics into widely accessible, reliable molecular testing at the point of care.

Read PDF

Similar papers

Review Open access Aug 2026

LAMP-CRISPR Integrated Platforms for Rapid Detection of Microbial Pathogens: Principles, Applied Strategies, and the Road to Field Translation.

This review provides a structured overview of current LAMP-CRISPR platforms and highlights key technological considerations for translating rapid microbial pathogen detection from laboratory research to real-world applications.

Yi Xu, Xiao-Jiao He, Tian-Le Xu · 0 citations
Review Open access Aug 2026

Research Progress in Applications of the CRISPR-Cas12b System in Pathogen Nucleic Acid Detection

A comprehensive evaluation of current applications demonstrates the efficacy of CRISPR-Cas12b-based diagnostics across diverse pathogens, including viruses, bacteria, and parasites, with a specific focus on its integration with isothermal amplification techniques.

Jiang-Ying Li, Xue-Yong Zhang · 0 citations
Review Sep 2026

From Lab to Clinic: Patient‐Based Validation of Microfluidic‐Isothermal Amplification Devices for Early Disease Diagnosis

Early diagnosis markedly improves therapeutic efficacy, recovery, and disease control. Microfluidic platforms based on isothermal nucleic acid amplification enable sensitive, rapid, and low‐volume detection of disease markers. This review provides a critical analysis of the integration of isothermal amplification tec...

T. Trinh, V. Dinh, Hanh An Nguyen et al. · 0 citations

One-Pot Isothermal Linear Amplification and Cas12a-Based Nucleic Acid Detection

CATNAP (Cas trans -nuclease detection of amplified products), a method that integrates isothermal linear DNA amplification with Cas12a detection in a single reaction, bridges the sensitivity gap in CRISPR diagnostics while maintaining simplicity, making accurate disease detection more accessible in resource-limited setti...

S. Sinan, Remy M. Kooistra, Karunya Rajaraman et al. · 0 citations
Open access Sep 2026

Harmonizing amplification and cleavage kinetics through crRNA scaffold mutation enables robust one-pot CRISPR-Cas12 diagnostics.

This work presents a broadly applicable one-pot detection strategy termed mutant scaffold-mediated RPA-CRISPR/Cas12a (MS-CRISPR), and introduces rationally designed point mutations into the crRNA scaffold to moderately attenuate Cas12a activation and cleavage kinetics.

Qing-Yang Jiang, Rui-Quan Xu, Zhi-Xin Lin et al. · 0 citations
Review Oct 2026

Molecular Programming of CRISPR Diagnostics: From Target Recognition to Field Deployment.

An integrated framework that connects five coupled design layers with five levels of translational evidence shifts the evaluation of CRISPR diagnostics from isolated analytical performance toward evidence-based workflow co-design.

Heng-Yu Wang, Mei-You Chen, Qiu-Run He et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.